Meningococcal disease: Challenges in prevention and management

Infections in Medicine

Volumn 17, Issue 5, 2000, Pages 364-377

  Leake, John A D ^a   Perkins, Bradley A ^b,c  

^a RADY CHILDREN'S HOSPITAL   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Epidemiology; Meningitis; Vaccination

Indexed keywords

CEFOTAXIME; CIPROFLOXACIN; MENINGOCOCCUS VACCINE; PENICILLIN G; POLYSACCHARIDE VACCINE; RIFAMPICIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; DRUG EFFICACY; HUMAN; INCIDENCE; MENINGOCOCCOSIS; REVIEW; VACCINATION;

EID: 0034115458     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Vieusseux M. Mémoires sur la maladie qui a regné à Genève au printemps 1805. J Med Chir Pharmacol. 1805;11:163.
2. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. N Engl J Med. 1997;337:970-976.
3. World Health Organization. Weekly Epidemiol Rec. Oct 17, 1997;42:313-318.
4. Gold R. Clinical aspects of meningococcal disease. In: Vedros NA, ed. Evolution of Meningococcal Disease. Boca Raton, Fla: CRC Press; 1987: 69-97.
5. Gotschlich EC, Austrian R, Cvjetanovic B, Robbins JB. Prospects for the prevention of bacterial meningitis with polysaccharide vaccines. Bull World Health Organ. 1978;56:509-518.
6. Wenger JD, Perkins BA. Patterns in the emergence of meningococcal disease. In: Scheld WM, Armstrong D, Hughes JB, eds. Emerging Infections 1. Washington, DC: ASM Press; 1998: 125-136.
7. Devoe IW. The meningococcus and mechanisms of pathogenicity. Microbiol Rev. 1982;46:162-190.
8. Swarley JS, Marfin AA, Edupuganti S, et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA. 1997;94:271-276.
9. van der Ende A, Hopman CT, Zaat S, et al. Variable expression of class 1 outer membrane protein in Neisseria meningitidis is caused by variation in the spacing between the -10 and -35 regions of the promoter. J Bacteriol. 1995;177: 2475-2480.
10. Virji M. Studies on the Molecular Mechanisms of Meningococcal Interactions With Human Cells. Toward Anti-Adhesion Therapy for Microbial Diseases. New York Plenum Press; 1996:113-122.
11. Cartwright K. Meningococcal Disease. Chichester, England: John Wiley & Sons; 1995.
12. Achtman M. Clonal properties of meningococci from epidemic meningitis. Trans R Soc Trop Med Hyg. 1991;85(supp 1):24-31.
13. Fischer M, Perkins BA. Neisseria meningitidis serogroup B: emergence of the ET-5 complex. Semin Pediatr Infect Dis. 1997;8:50-56.
14. Reeves MW, Perkins BA, Wenger JD. Epidemic-associated Neisseria meningitidis detected by multilocus enzyme electrophoresis. Emerg Infect Dis. 1995;1:53-54.
15. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969; 129:1307-1326.
16. Carlone GM, Wenger JD, Perkins BA, et al. Haemophilus influenzae type b, Neisseria meningitidis, Streptococcus pneumoniae, and Corynebacierium diphtheriae vaccines. In Rose N, ed. Manual of Clinical Laboratory Immunology. Washington, DC: ASM Press; 1997:458-169.
17. Densen P. Complement. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Vol 1. Philadelphia: Churchill Livingstone; 1994:58-78.
18. Ross SC, Rosenthal PJ, Berberich HM, Densen P. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J Infect Dis. 1987; 155:1266-1275.
19. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med. 1997;336:708-716.
20. van Deuren M, van der Ven-Jongekrijg J, Demacker PN, et al. Differential expression of pro-inflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis. 1994;169:157-161.
21. Griffiss JM, Yamasaki R, Estabrook M, et al. Meningococcal molecular mimicry and the search for an ideal vaccine. Trans R Soc Trop Med Hyg. 1991;85(suppl)S32-S36.
22. Moran AP, Prendergast MM, Appelmelk BJ. Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease. FEMS Immunol Med Microbiol. 1996; 16:105-115.
23. de Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992;340:1074-1078.
24. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR. 1997;46: (RR-10):24.
25. Centers for Disease Control and Prevention. Serogroup Y meningococcal disease - Illinois, Connecticut, and selected areas. United States, 1989-1996. MMWR. 1996;45:1010-1013.
26. Kupperman N, Malley R, Inklis SH, Fleisher GR. Clinical and hematologic features do not reliably identify children with unsuspected meningococcal disease. Pediatrics. 1999;103:e20.
27. Broome CV. The carrier state: Neisseria meningitidis. J Antimicrob Chemother. 1986;18(suppl A): 25-34.
28. Greenfield S, Sheehe PR, Feldman HA. Meningococcal carriage in a population of "normal" families. J Infect Dis. 1971;123:67-73.
29. Zangwill KM, Schuchat A, Riedo FX, et al. School-based clusters of meningococcal disease in the United States. Descriptive epidemiology and a case-control analysis. JAMA. 1997;277: 389-395.
30. Tappero JW, Reporter R, Wenger JD, et al. Meningococcal disease in Los Angeles County, California, and among men in the county jails. N Engl J Med. 1996;335:833-840.
31. Centers for Disease Control and Prevention. Control and prevention of meningococcal disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR. 1997;46(RR-5):1-10.
32. American Academy of Pediatrics. Meningococcal Infections. Red Book: Report of the Committee on Infectious Diseases. Elk Grove Village, Ill: 1997:357-362.
33. Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J. 1997;16:979-983.
34. Greenwood BM, Blakebrough IS, Bradley AK, et al. Meningococcal disease and season in sub-Saharan Africa. Lancet. 1984;1:1339-1342.
35. Moore PS, Hierholzer J, DeWitt W, et al. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. JAMA. 1990;264:1271-1275.
36. Centers for Disease Control and Prevention. Provisional cases of selected notifiable diseases prevented by vaccination. MMWR. 1997;46 (52/53):1263.
37. Pinner RW, Gellin BG, Bibb WF, et al. Meningococcal disease in the United States - 1986. J Infect Dis. 1991;164:368-374.
38. Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected areas,United States, 1989-1991. Mor Mortal Wkly Rep CDC Surveill Summ. 1993;42(2):21-30.
39. Centers for Disease Control and Prevention. Serogroup B meningococcal disease: Oregon, 1994. MMWR. 1995; 44:121-124.
40. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States: an emerging threat. JAMA. 1995;273:383-389.
41. Levine OS, Shaffer P, Haddix A, Perkins BA. Cost-effectiveness analysis for routine immunization with a quadrivalent meningococcal polysaccharide (A,C,Y,W-135)-protein conjugate vaccine in the United States. Abstracts of the Tenth International Pathogenic Neisseria Conference, Baltimore; September 8-13, 1996: 228-230.
42. Brandtzaeg P, Kierulf P, Gaustad P, et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis. 1989;159:195-204.
43. Cartwright K, Strang J, Gossain S, Begg N. Early treatment of meningococcal disease. BMJ. 1992;305:774.
44. Kirsch EA, Barton RP, Kitchen L, Giroir BP. Pathophysiology, treatment, and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J. 1996;15:967-978.
45. Jackson LA, Alexander ER, Debolt CA, et al. Evaluation of the use of mass chemoprophylaxis during a school outbreak of enzyme type 5 serogroup B meningococcal disease. Pediatr Infect Dis J. 1996;15:992-998.
46. Jackson LA, Tenover FC, Baker C, et al. Prevalence of Neisseria meningitidis relatively resistant to penicillin in the United States, 1991. J Infect Dis. 1994;169:438-441.
47. Stocker SA, Wenger JD, Tenover FC. Antimicrobial susceptibility testing of recent isolates of Neisseria meningitidis from the United States. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15-18, 1996; New Orleans. Abstract 64.
48. Oppenheim BA. Antibiotic resistance in Neisseria meningitidis. Clin Infect Dis. 1997;24(suppl 1):S98-S101.
49. Saez Nieto JA, Vazquez JA, Marcos C. Meningococci moderately resistant to penicillin. Lancet. 1990;336:54.
50. Galimand M, Gerbaud G, Guibourdenche M, et al. High-level chloramphenicol resistance in Neisseria meningitidis. N Engl J Med. 1998;339: 868-874.
51. Saez-Llorens X, McCracken GH Jr. Antimicrobial and anti-inflammatory treatment of bacterial meningitis. Infect Dis Clin North Am. 1999; 13:619-636.
52. Nadel S, Newport MJ, Booy R, Levin M. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis. 1996; 174:878-880.
53. Westendorp RG, Langermans JA, de Bel CE, et al. Release of tumor necrosis factor an innate host characteristic that may contribute to the outcome of meningococcal disease. J Infect Dis. 1995;171:1057-1060.
54. Giroir BP, Quint PA, Barton P, et al. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet. 1997;350:1439-1443.
55. Drapkin MS, Wisch JS, Gelfand JA, et al. Plasmapheresis for fulminant meningococcemia. Pediatr Infect Dis J. 1989;8:399-400.
56. Goldman AP, Kerr SJ, Butt W, et al. Extracorporeal support for intractable cardiorespiratory failure due to meningococcal disease. Lancet. 1997;349:466-469.
57. Malley R, Huskins WC, Kupperman AN. Multivariable predictive models for adverse outcome of meningococcal invasive disease in children. J Pediatr. 1996;129:702-710.
58. Zangwill KM, Stout RW, Carlone GM, et al. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. J Infect Dis. 1994;169:847-852.
59. Ceesay SJ, Allen SJ, Menon A, et al. Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization. J Infect Dis. 1993;167:1212-1216.
60. Reingold A, Broome CV, Hightower AW, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet. 1985;2: 114-118.
61. Ueberman JM, Chiu SS, Wong VK, et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children: a randomized controlled trial. JAMA. 1996;275:1499-1503.
62. Twumasi PA Jr, Kumah S, Leach A, et al. Atrial of group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis. 1995;171:632-638.
63. Campagne G, Garba A, Boulanger D, et al. Development of a meningococcal A/C conjugate vaccine [abstract]. Am J Trop Med Hyg. 1997; 57(suppl 3):129.
64. Centers for Disease Control and Prevention. Progress toward elimination of Haemophilus influenzae type b disease among infants and children, United States, 1987-1995. MMWR. 1996; 45:901-906.
65. Takala AK, Eskola J, Leinonen M, et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis. 1991;164:982-986.
66. Mohle-Boetani JC, Ajello G, Breneman E, et al. Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines. Pediatr Infect Dis J. 1993;12:589-593.
67. Imrey PB, Jackson LA, Ludwinski PH, et al. Outbreak of serogroup C meningococcal disease associated with campus bar patronage. Am J Epidemiol. 1996;143:624-630.
68. Jackson IA, Schuchat A, Gorsky RD, Wenger JD. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. Am J Public Health. 1995;85:843-845.
69. Zollinger WD, Moran E. Meningococcal vaccines - present and future. Trans R Soc Trop Med Hyg. 1991;85(suppl 1):37-43.